Invesco’s Viking Therapeutics VKTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $4.82M | Buy |
123,679
+11,340
| +10% | +$366K | ﹤0.01% | 2242 |
|
|
2026
Q1 | $3.66M | Buy |
112,339
+5,172
| +5% | +$166K | ﹤0.01% | 2308 |
|
|
2025
Q4 | $3.77M | Sell |
107,167
-2,130
| -2% | -$75.5K | ﹤0.01% | 2375 |
|
|
2025
Q3 | $2.87M | Buy |
109,297
+13,343
| +14% | +$398K | ﹤0.01% | 2477 |
|
|
2025
Q2 | $2.54M | Buy |
95,954
+10,973
| +13% | +$289K | ﹤0.01% | 2481 |
|
|
2025
Q1 | $2.05M | Sell |
84,981
-787,865
| -90% | -$24.9M | ﹤0.01% | 2541 |
|
|
2024
Q4 | $35.1M | Sell |
872,846
-3,376
| -0.4% | -$193K | 0.01% | 1201 |
|
|
2024
Q3 | $55.5M | Buy |
876,222
+168,343
| +24% | +$9.88M | 0.01% | 998 |
|
|
2024
Q2 | $37.5M | Buy |
707,879
+11,945
| +2% | +$783K | 0.01% | 1133 |
|
|
2024
Q1 | $57.1M | Buy |
695,934
+558,371
| +406% | +$24.8M | 0.01% | 974 |
|
|
2023
Q4 | $2.56M | Sell |
137,563
-727,026
| -84% | -$9.51M | ﹤0.01% | 2526 |
|
|
2023
Q3 | $9.57M | Buy |
864,589
+38,695
| +5% | +$553K | ﹤0.01% | 1788 |
|
|
2023
Q2 | $13.4M | Buy |
+825,894
| New | +$17.3M | ﹤0.01% | 1599 |
|
|
2023
Q1 | – | Sell |
-258,322
| Closed | -$2.43M | – | 4013 |
|
|
2022
Q4 | $2.43M | Buy |
+258,322
| New | +$1.15M | ﹤0.01% | 2570 |
|
|
2022
Q2 | – | Sell |
-24,713
| Closed | -$75K | – | 4150 |
|
|
2022
Q1 | $75K | Sell |
24,713
-34,635
| -58% | -$124K | ﹤0.01% | 3891 |
|
|
2021
Q4 | $273K | Sell |
59,348
-4,451
| -7% | -$24.9K | ﹤0.01% | 3654 |
|
|
2021
Q3 | $401K | Buy |
63,799
+4,886
| +8% | +$30.2K | ﹤0.01% | 3526 |
|
|
2021
Q2 | $353K | Sell |
58,913
-127,225
| -68% | -$755K | ﹤0.01% | 3564 |
|
|
2021
Q1 | $1.18M | Buy |
186,138
+16,996
| +10% | +$120K | ﹤0.01% | 2993 |
|
|
2020
Q4 | $953K | Buy |
169,142
+25,856
| +18% | +$157K | ﹤0.01% | 2951 |
|
|
2020
Q3 | $834K | Buy |
143,286
+940
| +0.7% | +$6.47K | ﹤0.01% | 2902 |
|
|
2020
Q2 | $1.03M | Sell |
142,346
-33,581
| -19% | -$223K | ﹤0.01% | 2791 |
|
|
2020
Q1 | $823K | Buy |
175,927
+37,879
| +27% | +$233K | ﹤0.01% | 2810 |
|
|
2019
Q4 | $1.11M | Sell |
138,048
-21,062
| -13% | -$154K | ﹤0.01% | 2949 |
|
|
2019
Q3 | $1.09M | Buy |
159,110
+28,081
| +21% | +$209K | ﹤0.01% | 2947 |
|
|
2019
Q2 | $1.09M | Buy |
131,029
+16,573
| +14% | +$142K | ﹤0.01% | 3023 |
|
|
2019
Q1 | $1.14M | Sell |
114,456
-15,681
| -12% | -$131K | ﹤0.01% | 2953 |
|
|
2018
Q4 | $996K | Buy |
130,137
+114,923
| +755% | +$1.37M | ﹤0.01% | 2979 |
|
|
2018
Q3 | $265K | Sell |
15,214
-447
| -3% | -$5.32K | ﹤0.01% | 3630 |
|
|
2018
Q2 | $149K | Buy |
+15,661
| New | +$104K | ﹤0.01% | 3743 |
|
Other funds holding VKTX
Invesco's VKTX Position: Q2 2026 in Review
Invesco increased its Viking Therapeutics (VKTX) stake by 10% in Q2 2026, buying an estimated $366K and bringing the position to 123,679 shares worth $4.82M. The position accounts for ﹤0.01% of the portfolio, ranked #2242.
Invesco first reported a position in VKTX in Q2 2018 and has held it in 30 quarters since. The position peaked at $57.1M in Q1 2024. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.
- Invesco held 123,679 shares of Viking Therapeutics worth $4.82M as of Q2 2026.
- Invesco bought 11,340 Viking Therapeutics shares in Q2 2026, an estimated $366K.
- Viking Therapeutics made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #2242 holding.
- Invesco first reported a position in Viking Therapeutics in Q2 2018 and has held it in 30 quarters since.
- Invesco's Viking Therapeutics position peaked at $57.1M in Q1 2024.
- 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.
Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.